The Experts below are selected from a list of 24018 Experts worldwide ranked by ideXlab platform
Ian R. Reid - One of the best experts on this subject based on the ideXlab platform.
-
Menopausal bone loss in long-term users of depot Medroxyprogesterone acetate contraception.
American Journal of Obstetrics and Gynecology, 2002Co-Authors: Tim Cundy, Jillian Cornish, Helen Roberts, Ian R. ReidAbstract:Abstract Objective: The purpose of this study was to determine the rate of early postmenopausal bone loss in women who had used depot Medroxyprogesterone acetate contraception through to menopause. Study Design: Bone mineral density at the lumbar spine and femoral neck was assessed prospectively over 3 years in 15 women who reached a natural menopause and who did not undergo hormone replacement therapy and in 16 long-term users of depot Medroxyprogesterone acetate who discontinued depot Medroxyprogesterone acetate only on reaching menopause. Of the latter, 5 women subsequently underwent hormone replacement therapy. Results: Early menopausal bone loss was rapid in the control group (6% from both sites over 3 years), but the users of depot Medroxyprogesterone acetate (who did not take hormone replacement therapy) showed little change in bone mineral density. Between-group differences were statistically significant at years 2 and 3 at both sites ( P P Conclusion: Women who use depot Medroxyprogesterone acetate through to menopause have attenuated rates of bone loss from the lumbar spine and femoral neck, presumably because they have already lost the estrogen-sensitive component of bone. (Am J Obstet Gynecol 2002;186:978-83.)
-
Spinal bone density in women using depot Medroxyprogesterone contraception.
Obstetrics & Gynecology, 1998Co-Authors: Tim Cundy, Helen Roberts, Jill Cornish, Hinemoa Elder, Ian R. ReidAbstract:Objective: To determine factors possibly associated with reduced bone density in women using the injectable contraceptive depot Medroxyprogesterone acetate. Methods: In a cross-sectional study, bone mineral density of the lumbar spine was measured by dual energy x-ray absorptiometry in 200 current users of depot Medroxyprogesterone acetate who had used this method of contraception for 2–26 years and compared with 350 control subjects. Bone density results are expressed as standard deviation scores (z score). Results: The bone density was significantly lower in depot Medroxyprogesterone acetate users (mean z score: −0.65, 95% confidence intervals [CI] −0.80, −0.49, P < .001). Bone density was significantly reduced in nonsmokers and smokers, and there was no significant difference in mean z score between smokers and nonsmokers (mean −0.75 versus −0.58, P = .30). Women who had started depot Medroxyprogesterone acetate after the age of 20 years and who had used it for 15 or fewer years had a significantly higher bone density than the remainder of the cohort (mean −0.45 [95% CI −0.62, −0.27] versus −1.02 [95% CI −1.32, −0.73], P < .005). Bone density in depot Medroxyprogesterone acetate users was not related to current age, parity, body mass index, calcium intake, or exercise. Conclusion: Depot Medroxyprogesterone acetate use is associated with a significant reduction in bone density, and although a high proportion of depot Medroxyprogesterone users do smoke, the reduction in bone density cannot be explained by smoking. Women who use it for a long time and those who start it before peak bone mass is attained may be at highest risk.
-
Spinal bone density in women using depot Medroxyprogesterone contraception.
Obstetrics and gynecology, 1998Co-Authors: Tim Cundy, Jillian Cornish, Helen Roberts, Hinemoa Elder, Ian R. ReidAbstract:To determine factors possibly associated with reduced bone density in women using the injectable contraceptive depot Medroxyprogesterone acetate. In a cross-sectional study, bone mineral density of the lumbar spine was measured by dual energy x-ray absorptiometry in 200 current users of depot Medroxyprogesterone acetate who had used this method of contraception for 2-26 years and compared with 350 control subjects. Bone density results are expressed as standard deviation scores (z score). The bone density was significantly lower in depot Medroxyprogesterone acetate users (mean z score: -0.65, 95% confidence intervals [CI] -0.80, -0.49, P < .001). Bone density was significantly reduced in nonsmokers and smokers, and there was no significant difference in mean z score between smokers and nonsmokers (mean -0.75 versus -0.58, P=.30). Women who had started depot Medroxyprogesterone acetate after the age of 20 years and who had used it for 15 or fewer years had a significantly higher bone density than the remainder of the cohort (mean -0.45 [95% CI -0.62, -0.27] versus -1.02 [95% CI -1.32, -0.73], P < .005). Bone density in depot Medroxyprogesterone acetate users was not related to current age, parity, body mass index, calcium intake, or exercise. Depot Medroxyprogesterone acetate use is associated with a significant reduction in bone density, and although a high proportion of depot Medroxyprogesterone users do smoke, the reduction in bone density cannot be explained by smoking. Women who use it for a long time and those who start it before peak bone mass is attained may be at highest risk.
Tim Cundy - One of the best experts on this subject based on the ideXlab platform.
-
Menopausal bone loss in long-term users of depot Medroxyprogesterone acetate contraception.
American Journal of Obstetrics and Gynecology, 2002Co-Authors: Tim Cundy, Jillian Cornish, Helen Roberts, Ian R. ReidAbstract:Abstract Objective: The purpose of this study was to determine the rate of early postmenopausal bone loss in women who had used depot Medroxyprogesterone acetate contraception through to menopause. Study Design: Bone mineral density at the lumbar spine and femoral neck was assessed prospectively over 3 years in 15 women who reached a natural menopause and who did not undergo hormone replacement therapy and in 16 long-term users of depot Medroxyprogesterone acetate who discontinued depot Medroxyprogesterone acetate only on reaching menopause. Of the latter, 5 women subsequently underwent hormone replacement therapy. Results: Early menopausal bone loss was rapid in the control group (6% from both sites over 3 years), but the users of depot Medroxyprogesterone acetate (who did not take hormone replacement therapy) showed little change in bone mineral density. Between-group differences were statistically significant at years 2 and 3 at both sites ( P P Conclusion: Women who use depot Medroxyprogesterone acetate through to menopause have attenuated rates of bone loss from the lumbar spine and femoral neck, presumably because they have already lost the estrogen-sensitive component of bone. (Am J Obstet Gynecol 2002;186:978-83.)
-
Spinal bone density in women using depot Medroxyprogesterone contraception.
Obstetrics & Gynecology, 1998Co-Authors: Tim Cundy, Helen Roberts, Jill Cornish, Hinemoa Elder, Ian R. ReidAbstract:Objective: To determine factors possibly associated with reduced bone density in women using the injectable contraceptive depot Medroxyprogesterone acetate. Methods: In a cross-sectional study, bone mineral density of the lumbar spine was measured by dual energy x-ray absorptiometry in 200 current users of depot Medroxyprogesterone acetate who had used this method of contraception for 2–26 years and compared with 350 control subjects. Bone density results are expressed as standard deviation scores (z score). Results: The bone density was significantly lower in depot Medroxyprogesterone acetate users (mean z score: −0.65, 95% confidence intervals [CI] −0.80, −0.49, P < .001). Bone density was significantly reduced in nonsmokers and smokers, and there was no significant difference in mean z score between smokers and nonsmokers (mean −0.75 versus −0.58, P = .30). Women who had started depot Medroxyprogesterone acetate after the age of 20 years and who had used it for 15 or fewer years had a significantly higher bone density than the remainder of the cohort (mean −0.45 [95% CI −0.62, −0.27] versus −1.02 [95% CI −1.32, −0.73], P < .005). Bone density in depot Medroxyprogesterone acetate users was not related to current age, parity, body mass index, calcium intake, or exercise. Conclusion: Depot Medroxyprogesterone acetate use is associated with a significant reduction in bone density, and although a high proportion of depot Medroxyprogesterone users do smoke, the reduction in bone density cannot be explained by smoking. Women who use it for a long time and those who start it before peak bone mass is attained may be at highest risk.
-
Spinal bone density in women using depot Medroxyprogesterone contraception.
Obstetrics and gynecology, 1998Co-Authors: Tim Cundy, Jillian Cornish, Helen Roberts, Hinemoa Elder, Ian R. ReidAbstract:To determine factors possibly associated with reduced bone density in women using the injectable contraceptive depot Medroxyprogesterone acetate. In a cross-sectional study, bone mineral density of the lumbar spine was measured by dual energy x-ray absorptiometry in 200 current users of depot Medroxyprogesterone acetate who had used this method of contraception for 2-26 years and compared with 350 control subjects. Bone density results are expressed as standard deviation scores (z score). The bone density was significantly lower in depot Medroxyprogesterone acetate users (mean z score: -0.65, 95% confidence intervals [CI] -0.80, -0.49, P < .001). Bone density was significantly reduced in nonsmokers and smokers, and there was no significant difference in mean z score between smokers and nonsmokers (mean -0.75 versus -0.58, P=.30). Women who had started depot Medroxyprogesterone acetate after the age of 20 years and who had used it for 15 or fewer years had a significantly higher bone density than the remainder of the cohort (mean -0.45 [95% CI -0.62, -0.27] versus -1.02 [95% CI -1.32, -0.73], P < .005). Bone density in depot Medroxyprogesterone acetate users was not related to current age, parity, body mass index, calcium intake, or exercise. Depot Medroxyprogesterone acetate use is associated with a significant reduction in bone density, and although a high proportion of depot Medroxyprogesterone users do smoke, the reduction in bone density cannot be explained by smoking. Women who use it for a long time and those who start it before peak bone mass is attained may be at highest risk.
-
Depot Medroxyprogesterone and bone density.
BMJ (Clinical research ed.), 1994Co-Authors: Tim Cundy, I ReidAbstract:EDITOR, - It is gratifying when publications arouse a vigorous debate, but the comments of correspondents on our paper1 are disappointing. Either our writing is not clear or the correspondents have not read the paper properly.Anne Szarewiski and colleagues say that we described the theoretical risk of oestrogen deficiency and osteoporosis in long term users of depot Medroxyprogesterone.2 Our study in fact showed that spinal bone density increased in women who stopped using depot Medroxyprogesterone …
Helen Roberts - One of the best experts on this subject based on the ideXlab platform.
-
Menopausal bone loss in long-term users of depot Medroxyprogesterone acetate contraception.
American Journal of Obstetrics and Gynecology, 2002Co-Authors: Tim Cundy, Jillian Cornish, Helen Roberts, Ian R. ReidAbstract:Abstract Objective: The purpose of this study was to determine the rate of early postmenopausal bone loss in women who had used depot Medroxyprogesterone acetate contraception through to menopause. Study Design: Bone mineral density at the lumbar spine and femoral neck was assessed prospectively over 3 years in 15 women who reached a natural menopause and who did not undergo hormone replacement therapy and in 16 long-term users of depot Medroxyprogesterone acetate who discontinued depot Medroxyprogesterone acetate only on reaching menopause. Of the latter, 5 women subsequently underwent hormone replacement therapy. Results: Early menopausal bone loss was rapid in the control group (6% from both sites over 3 years), but the users of depot Medroxyprogesterone acetate (who did not take hormone replacement therapy) showed little change in bone mineral density. Between-group differences were statistically significant at years 2 and 3 at both sites ( P P Conclusion: Women who use depot Medroxyprogesterone acetate through to menopause have attenuated rates of bone loss from the lumbar spine and femoral neck, presumably because they have already lost the estrogen-sensitive component of bone. (Am J Obstet Gynecol 2002;186:978-83.)
-
Spinal bone density in women using depot Medroxyprogesterone contraception.
Obstetrics & Gynecology, 1998Co-Authors: Tim Cundy, Helen Roberts, Jill Cornish, Hinemoa Elder, Ian R. ReidAbstract:Objective: To determine factors possibly associated with reduced bone density in women using the injectable contraceptive depot Medroxyprogesterone acetate. Methods: In a cross-sectional study, bone mineral density of the lumbar spine was measured by dual energy x-ray absorptiometry in 200 current users of depot Medroxyprogesterone acetate who had used this method of contraception for 2–26 years and compared with 350 control subjects. Bone density results are expressed as standard deviation scores (z score). Results: The bone density was significantly lower in depot Medroxyprogesterone acetate users (mean z score: −0.65, 95% confidence intervals [CI] −0.80, −0.49, P < .001). Bone density was significantly reduced in nonsmokers and smokers, and there was no significant difference in mean z score between smokers and nonsmokers (mean −0.75 versus −0.58, P = .30). Women who had started depot Medroxyprogesterone acetate after the age of 20 years and who had used it for 15 or fewer years had a significantly higher bone density than the remainder of the cohort (mean −0.45 [95% CI −0.62, −0.27] versus −1.02 [95% CI −1.32, −0.73], P < .005). Bone density in depot Medroxyprogesterone acetate users was not related to current age, parity, body mass index, calcium intake, or exercise. Conclusion: Depot Medroxyprogesterone acetate use is associated with a significant reduction in bone density, and although a high proportion of depot Medroxyprogesterone users do smoke, the reduction in bone density cannot be explained by smoking. Women who use it for a long time and those who start it before peak bone mass is attained may be at highest risk.
-
Spinal bone density in women using depot Medroxyprogesterone contraception.
Obstetrics and gynecology, 1998Co-Authors: Tim Cundy, Jillian Cornish, Helen Roberts, Hinemoa Elder, Ian R. ReidAbstract:To determine factors possibly associated with reduced bone density in women using the injectable contraceptive depot Medroxyprogesterone acetate. In a cross-sectional study, bone mineral density of the lumbar spine was measured by dual energy x-ray absorptiometry in 200 current users of depot Medroxyprogesterone acetate who had used this method of contraception for 2-26 years and compared with 350 control subjects. Bone density results are expressed as standard deviation scores (z score). The bone density was significantly lower in depot Medroxyprogesterone acetate users (mean z score: -0.65, 95% confidence intervals [CI] -0.80, -0.49, P < .001). Bone density was significantly reduced in nonsmokers and smokers, and there was no significant difference in mean z score between smokers and nonsmokers (mean -0.75 versus -0.58, P=.30). Women who had started depot Medroxyprogesterone acetate after the age of 20 years and who had used it for 15 or fewer years had a significantly higher bone density than the remainder of the cohort (mean -0.45 [95% CI -0.62, -0.27] versus -1.02 [95% CI -1.32, -0.73], P < .005). Bone density in depot Medroxyprogesterone acetate users was not related to current age, parity, body mass index, calcium intake, or exercise. Depot Medroxyprogesterone acetate use is associated with a significant reduction in bone density, and although a high proportion of depot Medroxyprogesterone users do smoke, the reduction in bone density cannot be explained by smoking. Women who use it for a long time and those who start it before peak bone mass is attained may be at highest risk.
Jillian Cornish - One of the best experts on this subject based on the ideXlab platform.
-
Menopausal bone loss in long-term users of depot Medroxyprogesterone acetate contraception.
American Journal of Obstetrics and Gynecology, 2002Co-Authors: Tim Cundy, Jillian Cornish, Helen Roberts, Ian R. ReidAbstract:Abstract Objective: The purpose of this study was to determine the rate of early postmenopausal bone loss in women who had used depot Medroxyprogesterone acetate contraception through to menopause. Study Design: Bone mineral density at the lumbar spine and femoral neck was assessed prospectively over 3 years in 15 women who reached a natural menopause and who did not undergo hormone replacement therapy and in 16 long-term users of depot Medroxyprogesterone acetate who discontinued depot Medroxyprogesterone acetate only on reaching menopause. Of the latter, 5 women subsequently underwent hormone replacement therapy. Results: Early menopausal bone loss was rapid in the control group (6% from both sites over 3 years), but the users of depot Medroxyprogesterone acetate (who did not take hormone replacement therapy) showed little change in bone mineral density. Between-group differences were statistically significant at years 2 and 3 at both sites ( P P Conclusion: Women who use depot Medroxyprogesterone acetate through to menopause have attenuated rates of bone loss from the lumbar spine and femoral neck, presumably because they have already lost the estrogen-sensitive component of bone. (Am J Obstet Gynecol 2002;186:978-83.)
-
Spinal bone density in women using depot Medroxyprogesterone contraception.
Obstetrics and gynecology, 1998Co-Authors: Tim Cundy, Jillian Cornish, Helen Roberts, Hinemoa Elder, Ian R. ReidAbstract:To determine factors possibly associated with reduced bone density in women using the injectable contraceptive depot Medroxyprogesterone acetate. In a cross-sectional study, bone mineral density of the lumbar spine was measured by dual energy x-ray absorptiometry in 200 current users of depot Medroxyprogesterone acetate who had used this method of contraception for 2-26 years and compared with 350 control subjects. Bone density results are expressed as standard deviation scores (z score). The bone density was significantly lower in depot Medroxyprogesterone acetate users (mean z score: -0.65, 95% confidence intervals [CI] -0.80, -0.49, P < .001). Bone density was significantly reduced in nonsmokers and smokers, and there was no significant difference in mean z score between smokers and nonsmokers (mean -0.75 versus -0.58, P=.30). Women who had started depot Medroxyprogesterone acetate after the age of 20 years and who had used it for 15 or fewer years had a significantly higher bone density than the remainder of the cohort (mean -0.45 [95% CI -0.62, -0.27] versus -1.02 [95% CI -1.32, -0.73], P < .005). Bone density in depot Medroxyprogesterone acetate users was not related to current age, parity, body mass index, calcium intake, or exercise. Depot Medroxyprogesterone acetate use is associated with a significant reduction in bone density, and although a high proportion of depot Medroxyprogesterone users do smoke, the reduction in bone density cannot be explained by smoking. Women who use it for a long time and those who start it before peak bone mass is attained may be at highest risk.
Hinemoa Elder - One of the best experts on this subject based on the ideXlab platform.
-
Spinal bone density in women using depot Medroxyprogesterone contraception.
Obstetrics & Gynecology, 1998Co-Authors: Tim Cundy, Helen Roberts, Jill Cornish, Hinemoa Elder, Ian R. ReidAbstract:Objective: To determine factors possibly associated with reduced bone density in women using the injectable contraceptive depot Medroxyprogesterone acetate. Methods: In a cross-sectional study, bone mineral density of the lumbar spine was measured by dual energy x-ray absorptiometry in 200 current users of depot Medroxyprogesterone acetate who had used this method of contraception for 2–26 years and compared with 350 control subjects. Bone density results are expressed as standard deviation scores (z score). Results: The bone density was significantly lower in depot Medroxyprogesterone acetate users (mean z score: −0.65, 95% confidence intervals [CI] −0.80, −0.49, P < .001). Bone density was significantly reduced in nonsmokers and smokers, and there was no significant difference in mean z score between smokers and nonsmokers (mean −0.75 versus −0.58, P = .30). Women who had started depot Medroxyprogesterone acetate after the age of 20 years and who had used it for 15 or fewer years had a significantly higher bone density than the remainder of the cohort (mean −0.45 [95% CI −0.62, −0.27] versus −1.02 [95% CI −1.32, −0.73], P < .005). Bone density in depot Medroxyprogesterone acetate users was not related to current age, parity, body mass index, calcium intake, or exercise. Conclusion: Depot Medroxyprogesterone acetate use is associated with a significant reduction in bone density, and although a high proportion of depot Medroxyprogesterone users do smoke, the reduction in bone density cannot be explained by smoking. Women who use it for a long time and those who start it before peak bone mass is attained may be at highest risk.
-
Spinal bone density in women using depot Medroxyprogesterone contraception.
Obstetrics and gynecology, 1998Co-Authors: Tim Cundy, Jillian Cornish, Helen Roberts, Hinemoa Elder, Ian R. ReidAbstract:To determine factors possibly associated with reduced bone density in women using the injectable contraceptive depot Medroxyprogesterone acetate. In a cross-sectional study, bone mineral density of the lumbar spine was measured by dual energy x-ray absorptiometry in 200 current users of depot Medroxyprogesterone acetate who had used this method of contraception for 2-26 years and compared with 350 control subjects. Bone density results are expressed as standard deviation scores (z score). The bone density was significantly lower in depot Medroxyprogesterone acetate users (mean z score: -0.65, 95% confidence intervals [CI] -0.80, -0.49, P < .001). Bone density was significantly reduced in nonsmokers and smokers, and there was no significant difference in mean z score between smokers and nonsmokers (mean -0.75 versus -0.58, P=.30). Women who had started depot Medroxyprogesterone acetate after the age of 20 years and who had used it for 15 or fewer years had a significantly higher bone density than the remainder of the cohort (mean -0.45 [95% CI -0.62, -0.27] versus -1.02 [95% CI -1.32, -0.73], P < .005). Bone density in depot Medroxyprogesterone acetate users was not related to current age, parity, body mass index, calcium intake, or exercise. Depot Medroxyprogesterone acetate use is associated with a significant reduction in bone density, and although a high proportion of depot Medroxyprogesterone users do smoke, the reduction in bone density cannot be explained by smoking. Women who use it for a long time and those who start it before peak bone mass is attained may be at highest risk.